Evolution Research Group   Report issue

For profit Phase 1 Phase 2
Founded: New Providence NJ United States (2002)

Organization Overview

First Clinical Trial
2013
NCT01948024
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Evolution Research Group

Active Ingredients

Drugs in Phase 2 Trials (1)

Key: Evolution Research Group (0) Acquired (1)

nb-002 (1 trial)

Drugs in Phase 1 Trials (2)

asenapine (saphris) (1 trial)

paliperidone (invega) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Bipolar Disorder (Phase 1)

Schizophrenia (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 3
  • # of Trial APIs: 3